Navigation Links
Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
Date:9/15/2008

d.

The overall response rate according to RECIST has been reported to be 43 percent in patients with high expression of EpCAM, the target of adecatumumab (3 of 7 patients), whereas no responses were detected in patients with low EpCAM expression (0 of 8 patients).

"These data demonstrate that adding adecatumumab to standard chemotherapy is feasible and suggest that the combination with taxanes could be a valuable treatment option for patients with high EpCAM expression," said Carsten Reinhardt, M.D., Ph.D., senior vice president and chief medical officer for Micromet. "The trend for a better outcome in patients with high EpCAM expression levels is in line with earlier observations and suggests a truly targeted effect of adecatumumab against EpCAM-positive tumor cells."

In addition to the continued clinical development in patients with breast cancer, Micromet is also in the process of setting up a randomized phase 2 clinical trial in patients suffering from colorectal cancer (CRC) after complete resection of first liver metastases.

(1) First results from a Phase 1b study of the anti-EpCAM antibody adecatumumab (MT201) in combination with docetaxel in patients with metastatic breast cancer. M. Schuler et al. ESMO Meeting Abstract, Sep 2008; Abstract 485P.

(2) Highly reduced incidence of new breast cancer metastases during treatment with adecatumumab appears to be the major factor for longer time to tumor progression in patients with high-level EpCAM expression Ch. Dittrich et al. AACR Meeting Abstract, Oct 2007; A71.

About ESMO

The European Society for Medical Oncology (ESMO) is the leading European non-profit professional organization for medical oncology, with a focus on promoting multidisciplinary cancer treatment around the world.

Since its founding in 1975, ESMO has continuously expanded its mission, aiming to create a wider community of people involved in the multifaceted aspects and phases of cancer: a com
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
3. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
4. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
5. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
6. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
9. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
10. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
11. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nk3569/future_horizons ... "Future Horizons and Growth Strategies in the European ... Forecasts" report to their offering. ... Blood Banking Market 2015 is a new five-countrystrategic ... and potential market entrants identify and evaluate emerging ...
(Date:7/1/2015)... , July 1, 2015 Rock Creek Pharmaceuticals, ... focused on chronic inflammatory disease and neurologic disorders, announced ... study with anatabine citrate, the Company,s lead compound. Results ... of anatabine citrate can significantly inhibit the activation of ... Company is developing this compound in a Phase 1 ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
Breaking Medicine Technology:European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3
... 12 CVS Caremark Corporation (NYSE: CVS ) today announced ... of approximately 15%, to 8.75 cents per share on the Common ... record on January 22, 2010 . This increase translates into an annual ... per share from the previous rate of 30.5 cents . , ...
... , ST. JOSEPH, Mich. , Jan. 12 ... announced today they have been awarded a $336K Phase I ... for creating a novel type of predictive signatures for drug ... should overcome many shortcomings of existing methods of molecular diagnostics. ...
Cached Medicine Technology:CVS Caremark Corporation Increases Quarterly Dividend 15% 2GeneGo Receives SBIR Grant 2GeneGo Receives SBIR Grant 3
(Date:7/1/2015)... ... July 01, 2015 , ... ... of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for Summary Judgment. ... West Virginia on June 26th, the Court rejected the Plaintiff’s assertion that ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... today announced that they will welcome four new members to their industry leading ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... natural forms, such as organically raised chickens and eggs. Eating organic foods and ... chickens is cleaner and more environmentally friendly than production chicken farming. Choosing home ...
(Date:7/1/2015)... York, NY (PRWEB) , ... July 01, 2015 , ... ... $100,000 from the New York Community Trust. The grant will allow CCF to improve ... sharing proven practices. , CCF was formed to respond to many changes in New ...
(Date:7/1/2015)... NY (PRWEB) , ... July 01, 2015 , ... Summer ... taboo with teenagers to fix noses and chins with plastic surgery when they’re looking ... Surgeons (ASPS) more than 236,000 cosmetic procedures were performed on patients ages 19 and ...
Breaking Medicine News(10 mins):Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 2Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 3
... The Breast, Cancer Patient Protection Act, Championed by ... DeLauro (D-CT) and Moran (R-KS) -, - Effort Part ... Campaign to Encourage Women to Speak Out on Issues That ... a Capitol Hill,press conference, actress Marcia Cross joined Lifetime and ...
... reward center, which can go awry , , WEDNESDAY, Jan. ... specific part of the brain handles what might be ... could lead scientists closer to more effective treatments for ... a brain region is helpful because it provides insight ...
... that field mice have evolved a unique way of ensuring ... infertility in humans. , The team, in collaboration with ... their immunity protection in favour of a more rapid fertilisation ... protein, called CD46. Present in both animals and humans, ...
... week cut death risk in half, study found , , WEDNESDAY, ... of exercise can dramatically prolong a man,s life, new research ... analysis -- the largest such study ever -- found that ... least four to six days a week was enough to ...
... KIRKLAND, Wash., Jan. 23 "A failing mind, ... care today," says Cameron,Truesdell, CEO of LTC Financial Partners, ... shouldn,t be, so we,re going to give,our clients information ... is offering a free guidebook and web links to ...
... Label Highlights CLARITIN Effectively Treats Indoor and ... Schering-Plough,(NYSE: SGP ) today announced ... has,approved additional labeling for CLARITIN(R) (loratadine), which ... relieves,allergy symptoms caused by both indoor (also ...
Cached Medicine News:Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 2Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 3Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 4Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 5Health News:Specific Brain Region Governs Problem-Solving Skills 2Health News:Specific Brain Region Governs Problem-Solving Skills 3Health News:Evolutionary phenomenon in mice may explain human infertility 2Health News:A Little Regular Exercise Extends Men's Lives 2Health News:A Little Regular Exercise Extends Men's Lives 3Health News:Long Term Care Insurance Leader Offers Advice on Preventing Dementia, the Leading Cause of Care Claims 2Health News:FDA Approves Labeling Change for Non-Drowsy CLARITIN(R) 2Health News:FDA Approves Labeling Change for Non-Drowsy CLARITIN(R) 3
2.5 mm x 0.6 mm. Overall length: 122 mm, 4.8 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: